Psyence BioMed agrees to invest up to USD 5 million in PsyLabs via share subscription

• Psyence Biomedical agreed to invest up to USD 5 million in PsyLabs, with USD 2.4 million irrevocably committed in its current financing round.
• Remaining up to USD 2.6 million set as a backstop subscription in up to two USD 1.3 million tranches, subject to milestones.
• Value-matched share exchange set at about USD 9 million each side, pending approvals, with a Nov. 30, 2026 termination date.
• Psyence BioMed to issue 1,497,500 common shares to PsyLabs at a deemed price of USD 6 per share.
• PsyLabs to issue 3,473 ordinary shares to Psyence BioMed, implying a PsyLabs equity valuation of USD 60 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230700PRIMZONEFULLFEED9832076) on September 23, 2026, and is solely responsible for the information contained therein.